Gastric Cancer Drug Pipeline Analysis Report 2025
Description
According to the World Cancer Research Fund International, approximately 968,784 new cases of gastric cancer were diagnosed in 2022 across the globe. Data suggests that gastric cancer ranks among the top three most common cancers in 19 countries and continues to be the leading cause of cancer mortality worldwide. The ongoing development of innovative and novel therapies shows a promising future for gastric cancer treatment.
Report Coverage
The Gastric Cancer Pipeline Report by Expert Market Research gives comprehensive insights on the gastric cancer emerging drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The gastric cancer report insights include the analysis of over 100 pipeline drugs and 50+ companies . Moreover, the analysis based on efficacy and safety measure outcomes published for the trials will be covered including their adverse effects in gastric cancer.
A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing gastric cancer pipeline development activities are covered.
Gastric Cancer Drug Pipeline Outlook
An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors , and Gastrointestinal Stromal Tumors (GIST).
Gastric cancer treatment depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immu notherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.
Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.
The gastric cancer report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.
Gastric Cancer – Drug Pipeline Therapeutic Assessment
This section of the gastric cancer pipeline report covers the analysis of gastric cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analysis based on phase.
EMR’s gastric cancer report assessment report covers 50+ drug analysis based on route of administration.
The gastric cancer pipeline landscape covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II trials cover major share of the total gastric cancer clinical trials conducted.
Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.
Gastric Cancer – Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under gastric cancer clinical assessment include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to EMR analysis , the parenteral route accounted for a major share of gastric cancer clinical trials.
Gastric Cancer – Pipeline Assessment – Competitive Dynamics
The EMR report for the gastric cancer drug pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:
The EMR gastric cancer drug profiles cover the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
Bemarit uzumab - Amgen
Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.
Everolimus - Novartis Pharmaceuticals
The purpose of the study is to evaluate the efficacy and safety of gastric cancer drug candidate RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.
Trastuzumab - Hoffmann-La Roche
The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate Human HER-2 status in gastric cancer.
DS-8201a (DP1) - Daiichi Sankyo Co., L td.
Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.
Key Questions Answered in the Gastric Cancer – Pipeline Assessment Report
Global Gastric Ulcer Treatment Market
North America Gastric Cancer Drugs Market
Global Cancer Therapeutics Market
Global Cancer Immunotherapy Market
Report Coverage
The Gastric Cancer Pipeline Report by Expert Market Research gives comprehensive insights on the gastric cancer emerging drugs currently undergoing clinical trials and covers various aspects related to the details for each of these drugs under development. The gastric cancer report insights include the analysis of over 100 pipeline drugs and 50+ companies . Moreover, the analysis based on efficacy and safety measure outcomes published for the trials will be covered including their adverse effects in gastric cancer.
A detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing gastric cancer pipeline development activities are covered.
Gastric Cancer Drug Pipeline Outlook
An abnormal cell growth in the stomach can lead to gastric cancer. Before the development of true cancer, pre-cancerous changes occur in the inner lining of the stomach. There are multiple types of gastric cancer which include adenocarcinoma of the stomach, Gastroesophageal Junction Adenocarcinoma (GEJ), gastrointestinal neuroendocrine tumors , and Gastrointestinal Stromal Tumors (GIST).
Gastric cancer treatment depends on the location of the cancer within the stomach and cancer stage. The treatment options include chemotherapy, targeted therapy and immunotherapy, radiation therapy and others. In 2021, the U.S. Food and Drug Administration amended its accelerated approval of the immu notherapy drug pembrolizumab (Keytruda) for treatment of advanced stomach cancer and gastroesophageal junction (GEJ) cancer.
Research studies shows that the drugs that target HER2 can be used to treat other cancers as well stomach cancer and GEJ cancer. Data suggests that 15% of patients with advanced stomach cancer have HER2-positive tumors. In November 2023, the U.S. Food and Drug Administration approved pembrolizumab combined with chemotherapy as an initial treatment for patients suffering from advanced stomach gastric that is HER2-negative.
The gastric cancer report covers the pathophysiology and epidemiology of gastric cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment in detail.
Gastric Cancer – Drug Pipeline Therapeutic Assessment
This section of the gastric cancer pipeline report covers the analysis of gastric cancer drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analysis based on phase.
- Late-Stage Products (Phase III and Phase IV)
- Mid-Stage Products (Phase II)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s gastric cancer report assessment report covers 50+ drug analysis based on route of administration.
- Oral
- Parenteral
- Others
The gastric cancer pipeline landscape covers phase I, phase II, phase III, phase IV, and early phase drugs for Gastric cancer. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II trials cover major share of the total gastric cancer clinical trials conducted.
Nivolumab developed by Bristol-Myers Squibb is currently under phase II. The purpose of the study is to assess the safety and efficacy of Nivolumab in combination with Ipilimumab for the treatment of advanced gastric cancer.
Gastric Cancer – Pipeline Assessment Segmentation, By Route of Administration
The route of administration categories covered under gastric cancer clinical assessment include oral, parenteral and others. The report covers a comparative analysis of the route of administration for each drug in various phases of clinical trials of gastric cancer. According to EMR analysis , the parenteral route accounted for a major share of gastric cancer clinical trials.
Gastric Cancer – Pipeline Assessment – Competitive Dynamics
The EMR report for the gastric cancer drug pipeline insight covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in gastric cancer clinical trials:
- Bristol-Myers Squibb
- AstraZeneca
- Enzon Pharmaceuticals, Inc.
- Amgen
- Novartis Pharmaceuticals
- Bayer AG
- Daiichi Sankyo Co., Ltd.
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- Others
The EMR gastric cancer drug profiles cover the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for gastric cancer. Moreover, the section covers product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.
Bemarit uzumab - Amgen
Amgen is conducting phase I clinical trials for bemarituzumab. The purpose of the study is to evaluate the safety and efficacy of bemarituzumab in combination with other anti-cancer therapies to treat multiple cancers including gastric cancer.
Everolimus - Novartis Pharmaceuticals
The purpose of the study is to evaluate the efficacy and safety of gastric cancer drug candidate RAD001 (Everolimus) monotherapy in patients suffering from advanced gastric cancer.
Trastuzumab - Hoffmann-La Roche
The study is under the observational phase and is sponsored by Hoffmann-La Roche. The primary purpose of the study is to evaluate Human HER-2 status in gastric cancer.
DS-8201a (DP1) - Daiichi Sankyo Co., L td.
Daiichi Sankyo Co., Ltd. Is conducting phase I trial to assess the safety of DS-8201a in participants suffering from advanced solid malignant tumors.
Key Questions Answered in the Gastric Cancer – Pipeline Assessment Report
- What is the current landscape of gastric cancer pipeline drugs?
- Which companies/institutions are developing gastric cancer therapeutic drugs?
- How many phase II drugs are currently present in gastric cancer pipeline drugs?
- Which company is leading the gastric cancer pipeline development activities?
- What is the current gastric cancer commercial assessment?
- What are the opportunities and challenges present in the gastric cancer drug pipeline landscape?
- What is the efficacy and safety profile of gastric cancer pipeline drugs?
- Which companies/institutions are involved in gastric cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in gastric cancer?
Global Gastric Ulcer Treatment Market
North America Gastric Cancer Drugs Market
Global Cancer Therapeutics Market
Global Cancer Immunotherapy Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Gastric Cancer
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Gastric Cancer
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Gastric Cancer: Epidemiology Snapshot
- 5.1 Gastric Cancer Incidence by Key Markets
- 5.2 Gastric Cancer– Patients Seeking Treatment in Key Markets
- 6 Gastric Cancer: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Gastric Cancer: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Gastric Cancer, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Gastric Cancer Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Gastric Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 XRP6976
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Masitinib
- 10.2.3 HX008
- 10.2.4 Tegafur
- 10.2.5 Other Drug
- 11 Gastric Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Pemetrexed
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 MEDI4736
- 11.2.3 Nab-Paclitaxel
- 11.2.4 Irinotecan
- 11.2.5 Other Drugs
- 12 Gastric Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Pemetrexed
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Promitil
- 12.2.3 5-Fluorouracil
- 12.2.4 Other Drugs
- 13 Gastric Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 NK510
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 IM92 CAR-T cells
- 13.2.3 Tcrx T cell
- 13.2.4 LCAR-C182A cells
- 13.2.5 Other Drugs
- 14 Gastric Cancer, Key Drug Pipeline Companies
- 14.1 Bristol-Myers Squibb
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 AstraZeneca
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Enzon Pharmaceuticals, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Amgen
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Novartis Pharmaceuticals
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Bayer AG
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Daiichi Sankyo Co., Ltd.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Daiichi Sankyo Co., Ltd.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Daiichi Sankyo Co., Ltd.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
